Concord Biotech Limited has announced the successful completion of an ANVISA inspection at its API manufacturing facility in Limbasi. The inspection, conducted by the Brazilian Health Regulatory Agency, took place from June 8 to June 12, 2026. This achievement marks a significant milestone, reinforcing the company’s commitment to quality and regulatory excellence, and strengthening its global manufacturing footprint and international expansion strategy.
ANVISA Inspection Concluded Successfully
Concord Biotech Limited is pleased to report the successful completion of an inspection conducted by the Brazilian Health Regulatory Agency (ANVISA). The inspection targeted the company’s API manufacturing facility located in Limbasi. The rigorous examination took place over several days, from June 8, 2026, to June 12, 2026, and concluded with positive outcomes.
Milestone for Global Growth
The successful conclusion of the ANVISA inspection represents a significant achievement for Concord Biotech’s global growth trajectory. This accomplishment underscores the company’s unwavering dedication to maintaining the highest standards of quality and regulatory compliance. It further solidifies Concord Biotech’s global manufacturing and regulatory presence, aligning with its strategic objective of international expansion.
Enhanced Market Access
This successful inspection is anticipated to enhance Concord Biotech’s access to one of the world’s largest pharmaceutical markets. It broadens the company’s ability to supply its high-quality APIs to key global geographies, reinforcing its position in the international pharmaceutical landscape.
Source: BSE
